On August 5, L’Oréal, one of the global giants in the beauty industry, announced the acquisition of a 10% stake in Swiss skincare company Galderma. L’Oréal purchased the shares from Sunshine SwissCo AG, a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd. The financial details of the transaction have not been disclosed.
This move follows the signing of a memorandum of understanding between the two companies to pursue a new research and development (R&D) collaboration. The partnership aims to focus on complementary research projects to develop advanced technologies in dermatology. Both Galderma and L’Oréal aim to accelerate innovation to deliver new levels of performance against the signs of skin aging.
Flemming Ørnskov, CEO of Galderma, stated, “We are delighted to welcome L’Oréal as a new, long-term Galderma shareholder and see their investment as a sign of confidence in our strategy, track record and growth potential. We look forward to pursuing scientific partnership opportunities together, for the benefit of the customers, patients and consumers we serve across the globe every day.”
Meanwhile, L’Oréal has agreed to customary stand-still and tender obligations with Sunshine SwissCo AG, and no changes are planned for Galderma’s Board of Directors or governance. Michael Bauer, Partner and Co-Head of Global Healthcare Sector at EQT, commented, “Selling a minority stake to a reputable strategic partner such as L’Oréal, the global leader in Beauty, is a direct reflection of our commitment.”
For over 40 years, Galderma has shown an unwavering commitment to skin science. With continuous investment in R&D, the company has remained at the forefront of the latest innovations in dermatology. This partnership with L’Oréal is expected to advance the development of new technologies and products in the rapidly growing dermatology market.